BioMark Diagnostics Stock

BioMark Diagnostics Net Margin

The Net Profit Margin of BioMark Diagnostics (BUX.CN) as of Jul 28, 2026 is -1,249.87 %. In the previous year, Net Profit Margin was -874.63 % — a change of 42.90% (lower).

Net Margin

-1,249.87 %

YoY

42.90%

Last updated:

Net Profit Margin of BioMark Diagnostics is 2026 -1,249.87 % . Net Profit Margin of BioMark Diagnostics was 2025 -874.63 % . It decreases by 42.90% lower compared to the previous year.

For BioMark Diagnostics, the net margin of -1,249.9% is down versus -461.6% a few years ago.

Access this data via the Eulerpool API

BioMark Diagnostics Stock analysis

What does BioMark Diagnostics do? BioMark Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMark Diagnostics stock

Net Profit Margin of BioMark Diagnostics is -1,249.87 % in 2026.

Access this data via the Eulerpool API

Margins — BioMark Diagnostics

All Key Metrics — BioMark Diagnostics